JAMA Cardiology
Original Investigation
February 21, 2024
Michael T.ÌýLu, MD, MPH; Heather Ribaudo, PhD; Borek Foldyna, MD; Markella V.ÌýZanni, MD; Thomas Mayrhofer, PhD; Julia Karady, MD, PhD; Jana Taron, MD; Kathleen V.ÌýFitch, MSN; Sara McCallum, MPH; Tricia H.ÌýBurdo, PhD; Kayla Paradis, MBA; Sandeep S.ÌýHedgire, MD; Nandini M.ÌýMeyersohn, MD; Christopher DeFilippi, MD; Carlos D.ÌýMalvestutto, MD, MPH; Audra Sturniolo, MS; Marissa Diggs, BA; Sue Siminski, MBA; Gerald S.ÌýBloomfield, MD; Beverly Alston-Smith, MD; Patrice Desvigne-Nickens, MD; Edgar T.ÌýOverton, MD; Judith S.ÌýCurrier, MD; Judith A.ÌýAberg, MD; Carl J.ÌýFichtenbaum, MD; Udo Hoffmann, MD, MPH; Pamela S.ÌýDouglas, MD; Steven K.ÌýGrinspoon, MD; REPRIEVE Trial Writing Group
open access
has multimedia
JAMA Cardiol. 2024; 9(4):323-334. 10.1001/jamacardio.2023.5661
This substudy of a randomized clinical trial investigates the effects of pitavastatin on noncalcified coronary artery plaque using coronary computed tomography angiography and on inflammatory biomarkers as potential mechanisms for major adverse cardiovascular event prevention.